Molecular Characterization of NS5A Resistance Associated Substitutions after Failure of Sofosbuvir/Daclatasvir Combination Therapy in Chronic Hepatitis C genotype 4a Infected Egy - Egyptian Knowledge Bank

285806

Molecular Characterization of NS5A Resistance Associated Substitutions after Failure of Sofosbuvir/Daclatasvir Combination Therapy in Chronic Hepatitis C genotype 4a Infected Egy

Article

Last updated: 05 Jan 2025

Overview Similar Items

Article

Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a

Article

The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients

Article

EVALUATION OF THE SAFETY AND RESISTANCE ASSOCIATED VARIANTS OF SOFOSBUVIR/DACLATASVIR AMONG EGYPTIAN PATIENTS WITH HEPATITIS C VIRUS: A PROSPECTIVE STUDY

Article

Efficacy and Safety of Daclatasvir and Sofosbuvir in Egyptian Patients with Chronic Hepatitis C Genotype 4 and Cirrhosis

Article

Characterization of Drug –resistance Profiles to Directly Acting Agents in Hepatitis C virus Naive Patients

Article

Efficacy and Safety of Sofosbuvir Based Therapy in Hepatitis C Genotype 4 Infection: Retrospective Review Medical Record

Article

Sofosbuvir plus Ribavirin for Treatment-Naïve Chronic HCV Genotype 4 Patients: Real-life Experience

Article

Safety and Efficacy of Direct Acting Antivirals (Sofosbuvir & Daclatasvir) in treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients

Article

Evaluation of Sofosbuvir plus Ribavirinin Treatment of Cirrhotic Hepatitis C Patients: An Egyptian Study

Article

Efficacy, Safety and Relapse of Sofosbuvir in Combination with Daclatasvir, Ledipasvir and Simeprevir for Treatment of Hepatitis C Virus in Egypt